BDBM410342 N-(3-((4aR,6R)-6-Hydroxy-1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,3-a][1,5]naphthyridin-9-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide and N-(3-((4aS,6S)-6-hydroxy-1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,3-a][1,5]naphthyridin-9-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide::US10377770, Example 102

SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2[C@H](O)C[C@@H]3COCCN3c2c1

InChI Key InChIKey=GMZOVVSCLMBIDH-WIYYLYMNSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 410342   

TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410342(N-(3-((4aR,6R)-6-Hydroxy-1,2,4,4a,5,6-hexahydro-[1...)
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent